Document Detail

Chronic central administration of apelin-13 over 10 days increases food intake, body weight, locomotor activity and body temperature in C57BL/6 mice.
MedLine Citation:
PMID:  18081555     Owner:  NLM     Status:  MEDLINE    
The peptide apelin has been located in a wide range of tissues, including the gastrointestinal tract, stomach and adipose tissue. Apelin and its receptor has also been detected in the arcuate and paraventricular nuclei of the hypothalamus, which are involved in the control of feeding behaviour and energy expenditure. This distribution suggests apelin may play a role in energy homeostasis, but previous attempts to discern the effects of apelin by acute injection into the brain have yielded conflicting results. We examined the effect of a chronic 10-day intracerebroventricular (i.c.v.) infusion of apelin-13 into the third ventricle on food intake, body temperature and locomotor activity in C57BL/6 mice. Apelin-13 (1 microg/day) increased food intake significantly on days 3-7 of infusion; thereafter, food intake of treated and control individuals converged. This convergence was potentially because of progressive conversion of apelin-13 to [Pyr(1)]apelin-13 which has a four-fold lower receptor binding affinity at the orphan G protein-coupled receptor, APJ. Locomotor activity was also higher in the apelin-treated mice, especially during the nocturnal peak, when most feeding occurs, and the first hours of the light phase. Body temperature was also elevated during this increased period of activity, but was otherwise unaffected. Apelin-13-infused animals gained more weight than the saline-infused controls, suggesting the elevated locomotor activity did not offset the increased food intake. Elevated locomotion and the consequent increases in body temperature were probably secondary effects to the increased food intake. These results suggest that apelin-13 may play a central role in the control of feeding behaviour and is one of only two peripheral ligands known to stimulate rather than inhibit intake. As apelin production is elevated during obesity, this may provide an important feed-forward mechanism exacerbating the problem. Antagonists of the apelin receptor may therefore be useful pharmaceuticals in the treatment of obesity.
A Valle; N Hoggard; A C Adams; P Roca; J R Speakman
Related Documents :
17920135 - Central visfatin causes orexigenic effects in chicks.
8067475 - 2-deoxy-d-glucose suppresses food intake through activation of hypothalamic histamine i...
1350985 - Effects on ingestive behavior in rats of the alpha 1-adrenoceptor agonist cirazoline.
12126995 - Intracerebroventricular administration of octopamine stimulates food intake of chicks t...
24702865 - Validity and reliability of the arabic version of the household food insecurity access ...
21683485 - Muscle protein synthesis in cancer patients can be stimulated with a specially formulat...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of neuroendocrinology     Volume:  20     ISSN:  1365-2826     ISO Abbreviation:  J. Neuroendocrinol.     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-12-17     Completed Date:  2008-04-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8913461     Medline TA:  J Neuroendocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  79-84     Citation Subset:  IM    
Grup de Metabolisme Energètic i Nutrició, Departament de Biologia Fonamental i Ciències de la Salut, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Balears, Palma de Mallorca, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Body Temperature / drug effects*
Body Weight / drug effects*
Drug Administration Schedule
Drug Stability
Eating / drug effects*
Feeding Behavior / drug effects
Injections, Intraventricular
Intercellular Signaling Peptides and Proteins / administration & dosage*,  pharmacokinetics
Mice, Inbred C57BL
Motor Activity / drug effects*
Time Factors
Reg. No./Substance:
0/Intercellular Signaling Peptides and Proteins; 0/apelin-13 peptide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Isolation and characterisation of four cDNAs encoding neuromedin U (NMU) from the brain and gut of g...
Next Document:  The anti-ghrelin Spiegelmer NOX-B11-3 blocks ghrelin- but not fasting-induced neuronal activation in...